MacuLogix has completed $38.7 million in Series D financing led by Vivo Capital, according to a press release.
The funds will be used to expand the company’s infrastructure in order to support the sales and practice integration of the AdaptDx automated dark adaptometer, which assists providers in detecting, monitoring and treating age-related macular degeneration, the release said.
“AMD is the leading cause of adult blindness in the Western world because we haven’t had the technology or tools to effectively detect and manage this progressive, chronic disease — until now.
Uncategorized